Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy of Nodular Goiter Allows Major Reduction of the Radiation Burden with Retained Efficacy | Zendy

Søren Fast | Zendy; Laszlo Hegedüs | Zendy; Peter Grupe | Zendy; Viveque Egsgaard Nielsen | Zendy; Christa Bluhme | Zendy; Lars Bastholt | Zendy; Steen Joop Bonnema | Zendy

Open Access

Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy of Nodular Goiter Allows Major Reduction of the Radiation Burden with Retained Efficacy

Author(s) -

Søren Fast,

Laszlo Hegedüs,

Peter Grupe,

Viveque Egsgaard Nielsen,

Christa Bluhme,

Lars Bastholt,

Steen Joop Bonnema

Publication year - 2010

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2010-0634

Subject(s) - medicine , placebo , goiter , thyroid , nuclear medicine , radioiodine therapy , urology , reduction (mathematics) , radiation therapy , placebo group , endocrinology , thyroid cancer , surgery , pathology , alternative medicine , geometry , mathematics

Stimulation with recombinant human TSH (rhTSH) before radioiodine (131I) therapy augments goiter volume reduction (GVR). Observations indicate that rhTSH has a preconditioning effect beyond increasing thyroid (131)I uptake. We test the hypothesis that an equivalent GVR might be obtained by an absorbed thyroid dose well below what has been used previously.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research